DALLAS, March 12, 2021 /PRNewswire/ -- Lantern
Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical
company using its proprietary RADR® artificial
intelligence ("A.I.") platform to transform oncology drug discovery
and development, today announced that an interview with CEO
Panna Sharma will air on The RedChip
Money Report® on Bloomberg TV in the US on Saturday, March 13, at 7
p.m. local time. The RedChip Money Report® also airs on
Bloomberg International in Europe
at 6 pm local time on Sundays.
In the exclusive interview, Sharma discusses Lantern Pharma's
current development pipeline, including its recently launched
Antibody Drug Conjugate program, multiple research and
development collaborations with leading cancer centers, and
upcoming milestones. To view the interview, please visit:
https://youtu.be/J-HKyn-JtiEhttps://youtu.be/u7G2l36rwn8.
"The RedChip Money Report" delivers insightful commentary on
small-cap investing, interviews with Wall Street analysts,
financial book reviews, as well as featured interviews with
executives of public companies.
Contact
Marek
Ciszewski, JD
Director, Investor Relations
628-777-3167
ir@lanternpharma.com
About Lantern Pharma
Lantern Pharma (LTRN) is a
clinical-stage biopharmaceutical company leveraging advances in
genomics, artificial intelligence, and machine learning by using
our proprietary RADR® A.I. platform to discover
biomarker signatures that identify patients most likely to respond
to our pipeline of cancer therapeutics. Our collaborator-centered
business model seeks out industry partners and leading scientific
advisors to capital-efficiently develop our pipeline of
genomically-targeted cancer therapeutics. Lantern is currently
developing three drug candidates and an ADC program across seven
disclosed targets, including two phase 2 programs, all focused on
cancers with unique and unmet clinical needs. By targeting drugs to
patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, this approach
represents the potential to deliver best-in-class outcomes. More
information at www.lanternpharma.com and Twitter
@lanternpharma.
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug
candidates and patient populations that are likely to respond to a
drug candidate; our strategic plans to advance the development of
our drug candidates and antibody drug conjugate (ADC) development
program; estimates regarding the development timing for our drug
candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "aim," "should," "will," "would," or the negative of
these words or other similar expressions) should be considered
forward-looking statements. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as (i) the impact
of the COVID-19 pandemic, (ii) the risk that we may not be able to
successfully initiate, conduct, or conclude clinical testing for or
obtain marketing approval for our product candidates; (iii) the
risk that no drug product based on our proprietary RADR A.I.
platform has received FDA marketing approval or otherwise been
incorporated into a commercial product, and (iv) those other
factors set forth in the Risk Factors section in our Annual Report
on Form 10-K for the year ended December 31,
2020, filed with the Securities and Exchange Commission on
March 10, 2021. You may access our
Annual Report on Form 10-K for the year ended December 31, 2020 under the investor SEC filings
tab of our website at www.lanternpharma.com or on the SEC's
website at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-interview-to-air-on-bloomberg-tv-in-the-us-on-the-redchip-money-report-301246448.html
SOURCE Lantern Pharma